Boom Lift,Reliable Boom Lifts,Electric Boom Lift,Boom Lifts On Tracks Jiangsu Minnuo Group Co.,Ltd , https://www.jsminnuomachinery.com
Pharmaceutical foreign trade "out of the limelight"
Zhou Xiaoming said that data from January to October this year showed that the pharmaceutical industry and export situation in China still maintain a relatively healthy fundamentals. The import and export volume of medical and health products continued to grow at a relatively fast pace. It has exceeded the US$40 billion mark, an increase of 30.7% year-on-year, and each of the import and export data has reached a record high. "The current statistics from the Ministry of Commerce show that pharmaceutical foreign trade is the only industry that has grown by more than 30%."
According to statistics, China's total exports during the January-October period was 26.8 billion U.S. dollars, an increase of 35.2% year-on-year, and the growth in exports of Western medicine and medical device products was more than 30%. Moreover, despite some adjustments in individual market rankings, there has been no major change in the pattern of foreign trade market formation for a long time. Asia, Europe and North America are China’s top three trading partners.
From January to October, China’s total imports and exports to the Asian region reached US$14.891 billion, of which export value was US$10.41 billion, an increase of 28.25% over the same period of last year. The total volume of imports and exports to the European region was US$ 14.21 billion, of which exports amounted to US$ 7.728 billion, an increase of 38.08% year-on-year. The total volume of foreign trade in the North American region was US$ 8.099 billion, of which the value of exports was US$ 5.453 billion, an increase of 36.98% year-on-year.
Zhou Xiaoming believes that under the global economic downturn, China's pharmaceutical foreign trade is still growing reasons: First, the pharmaceutical industry has a rigid demand; Second, China's raw material medicine, medical equipment and other industries in the international market have a certain degree of competitiveness; Third, India and other countries The product can not replace China's products; Fourth, the current data are basically the first half of the order.
A number of foreign and authoritative consulting agencies also revealed recently that China’s pharmaceutical industry has become a new destination for international investment funds with its steady growth. The future prospects of China’s pharmaceutical industry are generally optimistic.
Spread to individual areas
Although the pharmaceutical industry and export situation in China still maintain a relatively healthy fundamental, the impact of the financial turmoil has hit the individual areas of foreign trade in medicine. The pharmaceutical companies listed overseas in China are the first to suffer.
According to Xu Ming, Director General of the Chamber of Commerce of the Chamber of Commerce, at present, there are more than 20 pharmaceutical companies listed on the New York Stock Exchange, Nasdaq, etc. in the United States, including Shenzhen Mindray, Xiansheng Pharmaceutical, Wuxi Yaoming Kangde, etc. The well-known enterprises in the industry, except Shenzhen Mindray's stock price has remained relatively stable, the existing stock prices of other pharmaceutical companies have fallen below the initial issue price.
Many companies have reported that the average amount of single orders in foreign countries has shown a downward trend, which is characterized by shorter order terms, lower single-order amounts, and mainly orders from old customers. Some small and medium-sized massager manufacturers stated that they are generally afraid to pick up new orders due to the negative outlook on psychological expectations. They are generally worried that there will not be enough funds to organize production after the orders are received. At the same time, upstream supporting manufacturers are unwilling to advance due to financial constraints. The production of supporting products has increased capital pressure on companies.
In addition, a CEO of the participating companies mentioned that in addition to the impact of the financial crisis, Chinese-made products also began to face new challenges: First, the credibility crisis, because the price of export products rose in the first half of the year is too large, and some companies do not perform the original The low price contract signed; the second is the product quality crisis, mainly the “Sanlu milk powder incidentâ€, which has caused many foreign customers to lose confidence in the quality of Chinese products.
"Cold winter" will appear in March and April next year
"The real crisis in the industry may occur in March and April next year." Zhou Xiaoming said that according to the economic law, the pharmaceutical industry responds to the crisis about half a year slower than other industries. Therefore, the situation of medical foreign trade next year is not optimistic.
According to a survey conducted by the Chamber of Commerce at the Canton Fair concluded in November on 100 pharmaceutical companies, 50.8% of companies believe that international demand will decline next year, 24.6% believe that export value will decline, and 28.8% believe that the number of exports will decrease.
Faced with the current situation of the international economy and China's import and export of medical and health products and the problems faced, Zhou Xiaoming believes that relevant government departments maintain the continuity and stability of related policies. From the perspective of ensuring that Chinese pharmaceutical products have comparative advantages and reducing their operational risks, it is recommended that the tax rates that have been adjusted downwards should be adjusted upwards and expanded in order to maximize the benefits of Chinese pharmaceutical products. , characteristic raw materials, small and medium-sized medical devices with added value, etc.
In addition, it should also provide preferential support through CITIC Baohe Import & Export Bank, etc., to serve the majority of SMEs in a more flexible and timely manner. In addition, the Export-Import Bank and the Development Bank can also provide preferential low-interest or even interest-free loans for industry players.
Foreign trade in medicine: 08 years of independence
Zhou Xiaoming, president of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, disclosed on the 12th annual meeting of the Chamber of Commerce that the global economic recession will have a severe impact on the pharmaceutical industry in the United States and Europe, and the global pharmaceutical economic growth rate will fall by 1-2% next year. It is expected that the real impact on China's pharmaceutical industry will likely emerge in March and April next year.